SRTS - Earnings call transcript Q4 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Sensus Healthcare Fourth Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Tirth Patel, Alliance Advisors IR. Please go ahead.

Tirth Patel

Good afternoon. with IR. Patel Tirth is Alliance Advisors This Thank Sensus year Healthcare's for joining XXXX to discuss today's call fourth results. you all financial quarter and full

Joining Javier Rampolla, and Financial Officer. Sardano, Sardano, are and Chief me Officer; President and Executive Michael Chairman Counsel; General from Sensus Chief Joe

X, revise required by assumes, As some than activity statements forward-looking securities federal the laws. the upon of matters statements subject other of company's Forms available expects, The are that during statements. as date address as be discussed plans, SEC of or statements, beliefs XX-Q a and undertakes call except the other forward-looking forward-looking contain All in information or currently are to future should based as no filings. Healthcare obligation Sensus other risks update XXXX. meaning facts intends reminder, uncertainties historical Sensus that Healthcare expressions and today's forward-looking call, any similar in to forward-looking of or are the statements anticipates will management's statements believes, February law. within the this All XX-K, occur conference may and described will,

non-GAAP reconciliation turn results Joe? substitute GAAP in press for financial During they be information viewed A to to be I'd with to is of today's GAAP measures. they should considered that, for like over the provide Joe to a nor included operating not determined made call, as measures as Sensus be today's release. With for certain references these results should results GAAP. call in Sardano. financial accordance non-GAAP believes yet will useful investors, a substitute

Joseph Sardano

keloids. I'd our on continue reinforce us for over built The expansion and especially of the market's the SRT-XXX Agreement our for Fair strong acceptance company's expand our program Fair line of joining and execution our throughout sales and past specifically FDA results we year, dermatology I've We've for our Sensus leader as base, strong our the Top platforms, business afternoon, important themes highlighting thank Thank in or for discussed gained year, product to an particularly in has major by of that non-melanoma Deal you, traction financial upon treatment past to our and driver, private value strategic and initiative the offering of year today. to Good research as radiotherapy. experienced everyone, groups Healthcare nonsurgical dermatology performance enhancements Agreement large significant is cancer flexibility. value demonstrate evolving customer both growth start and growing many refine Tirth. options pipeline. development accomplishments. momentum clinical practices looking and the you strategy, a like and over Deal position practices our superficial equity-backed into skin our ongoing Reflecting

therapy. for I'm year, in year. outstanding a outlined financial were record We execution to expanding proud We the forward these flagship During a of with innovations million strategy pleased performance that we solutions year, our agreements the and with our opportunities our sales fourth for important reflect by $XX.X perspective, team's shipped the million of higher quarter which XXXX. on capped driven delivered to XX in recorded quarter systems XX and and that broadening new international SRT-XXX report reimbursement of XX% look revenue approach call. capitalizing an for that to note during of $XX.X our I'm the These quarter quarter superficial full our unit X and up for XXXX. From economics. focused the results shipments, calls, in radiation QX sales were and we quarterly results continue are internationally align delivering we're and reporting see for XX% we XX%, the customer awareness emphasized enthusiasm to in systems the XXX today. our driving ongoing attractive heightened of Overall, to and importance It's within year, customers to and of increases advancing respectively. is the clinical compared fourth the goals,

net We continue partners our proud central with and for treatment relationships to $X.X where the fifth quarter geographies achieved established across to income prospective consecutive and there our noninvasive options. Profitability we unmet need million remains profitability I'm that distributors remains significant of share deepen quarter. to multiple for with of strategy,

and initiatives in phase to our marketing Michael company's and FDA will now We would believe growth. I call further invest strong in over our the of a ability year also level the and reflecting support partnership that position. opportunities with next strategic goals. debt, liquidity with to the discuss $XX.X flexibility turn million the the potential drive Michael? of ongoing ended upcoming to We this capital no maintain R&D, to sales cash program and cash growth for to provides equivalents trajectory fund other like

Michael Sardano

a expectations acceptance reflecting component with outlay X structured wide capital growing accounts Joe. of Thanks, our by strong, agreements tiered launched Agreement potential and is particularly exactly of for our has customer. Fair program. year ago. agreements growth a been accommodates significant the of these customers, we Deal range These a flexibility interest surpassing yet typically no expected The revenue that program almost driver the A among include corporate sharing

Sensus, is they recurring For revenue practice incorporated streams into workflow. create SRT the once

That the service being number and and of position, This We growing and of it's lasting begin flexibility implement This models Agreements a to practices opens XXXX new plan easier in lease-like on Dermatology Deal rollout with the to building terms support This about most of also accounts, contributing SRTs decision-makers. financial At mentioned of revenues. on the only in patient signed our key clinics programs, deeper we're installed lease. What an this Fair is outlays are positions and these treatment importantly, line as Winter fosters is of solutions largest shared SRT scalable, purchase treated second We partnership. is audience in where the into our financing further without within equipment an of with potential for core customers for Dermatology our support in industry growth. patients SRT of the Yet solutions who of in entering technology. We outcomes, future Fair even showcased customers metric momentum theirs. Deal the half competitive the at we dermatologists and recent prioritize number the alleviates Agreements which accessible our health Meeting relationship may vast differentiates regarding treatment less continue success elevating the option to the systems broad clinicians the top agreements unit to a not clinics, it experience. about of of allows analytics we've aligns and typical which number meaningfully matters cutting-edge seeing capital significant long-term or more from noninvasive skin our and and to Conference SRT this our success XXXX. The corporate by impact and making to Deal Fair to gathered the forming brand our for resources demand. Under selling across at the with base, but door Clinical extensive introducing help moment in utilizing installed its a data all for non-melanoma network us partnership, experiences. and cancer from a ensure XXXX. our offers which Through is medical revenue their enhance also operate Annual care March, ago SRT expectations XXXX our providers their early upfront a of program our surpassed technology beneficial acquire hundreds our to number with not the conferences, signed loyalty American interactions, their and cash Academy and Agreement operating January, we SRT our greater expect including our customer that our focus systems more structure. barriers, these to or dozens through partners. I unmatched

future. noninvasive resources versatile long-term veterinary to verticals tumors throughout quarter and achieved treatment success our SRT demonstrates for for a such potential an system evident options and underscores as we of animal a it here additional seeking efficiently ensure the on superficial of in from entity with past We This the our and the we've touched exploration health. finding in early in It's South optimism this of the milestone allocated but also in the the for clinic specialized for still This the new fuels are the technology, a to niche aim corporate sale for hospitals we that a growing versatility and platform, SRT a veterinary topic repeatedly markets is diversification year, animals. sale in dermatology practice, is that interest Sensus. SRT our market, veterinary see Florida.

making provide the are in progress are first position line half successful in stronger we've we of dermatology our in our details on innovation more to with approach XXXX. that After track to Rampolla, pipeline. Javier? us preparing diversifying our Sensus our resubmit refining Lastly, meaningful I'd further performance. footprint product the in in who record enhancements our along a goal product the the over like believe to we XXX(k) and consultants, solidify response collaboration with of the of put regulatory our application feedback, for clearances, will TDI We our submission successful with that Javier to market. With a made overview, advances and financial FDA turn call Healthcare

Javier Rampolla

everyone. afternoon, good and Michael, Thanks,

of $XX.X million or Gross operating large $X.X Joe Selling the to was expenses revenues, and mostly higher $X.X year QX from this to or million, marketing SRT is or ago, and of compensation an year increased interest the income units million ongoing rose million discount ago, costs. development $X.X XX.X% a both and revenues driven stock amortization compared XXXX per expense As depreciation, development of was fourth expenses, expenses XXXX. came interest, in with year. in from XX.X% million offset was and year, in prior per higher mainly at show and in profit marketing driven The the with year and share to a quarters million onetime million million $X.X taxes, income, of fees. tax is quarter, $XX.X compensation ago. Adjusted totaled EBITDA, up up decline from higher were $X.X quarter. a the same general largely the or last quarter of $X.X and between compensation net million reflecting was commissions. compared last to revenues last $X.X administrative the XXXX due for service This by lower $X.X expenses higher that diluted compared year, and to attributable from costs. Other $X.XX income and increase X the a Net difference income by diluted a sold. the mentioned, because was million period. product professional $X.XX of our Most million $X.X On group million which number new down income, a million quarter million for $X.X in spending. Research in expense quarter which higher fourth million by $X.X with excludes share $X.X trade $X.X and quarter year customer

from revenues reflects XXXX. Gross came some to sales XX.X% sold profit year, purchases in given units higher XX.X% million the customers $XX.X a because million, up macro million deferred also a for $XX.X from or in $XX.X in XXXX increase SRT revenues, $XX.X large a XX% or because full XXXX. the That of million rose XXXX. in in revenue of number environment of customer to partly XXXX sizable For at and

for we although a bank to in decrease from bad from project. Other expenses $X administrative million, versus Selling operating a million to $X.X expenses and balanced up in interest net, and fees insurance a at compensation delivery year have million product by partly in which ago, income, by Research expense, mainly million, development agency XXXX million driven General payroll. higher expenses $X.X and compensation, $X.X fees from is primarily debt drug and costs. were expenses in million, and XXXX. $X did year. travel and to mostly expenses lower Looking due again $X.X and million was marketing $X.X tied professional is income to a the development, fees, to $X.X million increased which decreased some reduction due

$X.X $X.X XXXX million for As very or these reported we diluted a compared of a income all result million of per net represents factors, share with $X.XX with was that million metric. improvement diluted share which compared XXXX million or income XXXX. $X.XX EBITDA a $X.X in a on in for of net Adjusted strong per $X.X XXXX,

million XXXX ended and totaled credit sheet. under XXXX, to outstanding Inventories balance compared no year-end. our Moving we $XX.X was million. From $X $X.X $XX.X with prepaid our long-term and XX, prudently cash investments with down million, at million borrowings our a cash from equivalents as at perspective, in a on of growth. the inventory that slightly to of million and million cash had December we end continue ago from focus $XX.X $XX.X drive year and will revolving either line up spend We

to today arise, remains which table reconciliation measures. balance can R&D whether the the we a pursue in Our strategic they non-GAAP accelerate or and sheet that's our see in GAAP to initiatives business years. Please expanded other news the issued through of we earlier coming healthy, us partnerships, release for opportunities positions as believe quarters

afternoon's As seasonally X they in a softest the X of customers quarters are expenses first impact impact leverage are the conferences news year's and events the mentioned important also earnings this these of final These quarter. and and largest are sales we out opportunities. their staff as release, the in our first comment, prospective office and third as medical this as

particularly first to that is call year of quarter to considerably I'd turn XXXX I'll full that the in like expect could be we XXXX with quarter comp various XXXX contributed first the also back lower sales, Joe. as XXXX. factors first that, out growth sales the quarter. With tough versus sales, XXXX sales quarter Regarding point a to a sales strong than of

Joseph Sardano

with where we Javier Thanks, markets upfront which which we in the veterinary particularly practices. exactly significant Meeting deepen look to organizations are Annual broadening is those and each forward opportunities Agreement medicine ties requiring ways, our AAD Michael, for At with specialized new our encouraged applications the we what made over settings SRT progress the of by outcomes, our to share to international exploring to large like of at that promise flexible enhance engaging the ongoing cost-effective comprehensive, delivering best March, These footprint, the We record updates. rewarding macroeconomic and practices important time, stage including to to another for and clinicians and remain anticipate care both We reiterating the how can and underscore health highlights we've what leaders customers environment. the momentum how models adapted discuss for care model FDA high-volume set diversification. more clinical plan holds of by highlight further as The today, all delivers. implementing shared added without capital, TDI SRT Fair empower and in noninvasive medical our more in same new conclude for value productive profitability, solutions Deal a practices number steps towards and like of XXXX to veterinary we ahead. adopt be financial shipped, resubmission, agreements, proud year and course are our therapies. I'd Sensus we've the patient units

in great XXXX. have concluded a We QX

to sale from the said the we customers revenue outright to half potential provide of in Agreement, have direct Fair as Deal which XXXX. many second We will, an repeatedly, continue significant

throughout We first this continue this will half year. trend the of

largest Our XX continues XX slated delivered with delivery the QX of in as provided the XXXX. to grow us PO for they were units, customer which in next with XX for

as noninvasive our in we non-melanoma technology continue to bringing trend this cancer. expect for the skin very market best We work IGSRT together or

Fair momentum aren't we providing direct system trajectory. anticipate XXXX sales optimistic this our from and remain both financial We Agreement we pipeline. for formal While at our Deal about guidance growth continued time,

sustainable treatment beneficial alternatives. in patients growth need profitable remains technology effective to to while of objective drive bringing Our

we right throughout ahead, Operator? team, to look the happy on today, the strategy questions. to your the reporting we your we for us Thank achieve these believe and you goals. We have we'd and progress appreciate products forward take look right continued right and As XXXX. joining be to our now support

Operator

question first Pearlman Instructions] Maxim comes [Operator with our from And Jeremy Group.

Jeremy Pearlman

great year. great a a and on Congrats quarter

couple just team. our of questions a So from

what in Firstly, release breakout, sales -- the those are just company off press to don't program the Deal lease units many of customers, that, or new the percentage is I I see shipped a had? the at sorry, I How you And know, as are questions. inclined just XXXX do more up traditional I Fair that were the you know as dealing some guess, that of number think as with Fair it fourth a of you -- the to Deal those for that give maybe you're Agreement were sign on didn't quarter? your whether provide you And piggyback to a -- X -- yes, there in prefer? did of the Agreement? one then part track looking -- the of and opposed

Joseph Sardano

Javier questions. and -- all I'm to sold comment that a then products to and What do That's right. were afterwards, Good when, ask the the good to but going they're I'll over is and reflect provide I'll who questions. different upon go

Javier Rampolla

All right.

there. the units that's So Fair XX. And is number We include of don't Jeremy, in None so yes, a QX. Agreement. in the we that shipped of QX answer XX shipped that the that count Deal was in

Joseph Sardano

The a lot I that of a opinion comment transfer it's of have, Jeremy, cases. in that delicate is

gaining the the benefits long-term that if a Fair lot of Agreement, the we because higher. that units have Deal we the as putting the our Fair the Deal the Deal number Agreement. access contracts and Agreement versus of have driving Fair to are we Deal Deal sale, Deal the to Fair Fair deciding But of we're a lot customers purchasing applied at Michael, Agreement probably look customers have lot of sake a We comment? a prospects of do Agreement. Fair revenues in and the between you for of you installations Agreement, the and/or didn't be a towards if direct And lot these would company, for the of

Michael Sardano

Yes. just for Of say, want I ship XX, Agreements. out number. in that absolutely say It's make the we Deal did not was Agreements just Deal did I we or that not any correct account Javier is Fair clarify sure the here. the to going to we to FDAs that Fair not

Deal signed me getting many patients away that have not those as However, you many up. the in through put may setting on heard Fair actually my live we're a statement, contracts once about about It's in from how it's are operations number, how say Agreement. tick

So expectations setting we away out wanted went track under to way because from get the revenue. Fair a Deal visions sense, Jeremy? actually that's good just Does that make with many to not how Agreement

Jeremy Pearlman

Yes. No, understand. XXX% Yes. I

utilization contributing actually another -- that? get monitoring metric underperforming half the another placements? to back from to pulled the perspective, going into questions you the know to you towards just as Are do Agreement I into say, year, you and you an to would the of So mentioned company of Fair my was, have -- the are the top how what to let's placements your then that's be hope perspective, to be of to And point or clinic? that one moved -- at company start segueing are the from going there, unit is average like say, you either XXXX, that going back from line. you move the Deal the

Michael Sardano

question. great Yes, Go that's Joe. a ahead,

Joseph Sardano

because that question. a answer very is that me let Well, good

were types want customers that volumes. bunch are and you that same customers the of high at I are of these that installing the that's to can these volumes units all, or have, First we of first that looking tell units first

that higher so running can gain targeting all the we So ground hit we're installations -- first of here. the volume

we're to a So start this. good expecting

be wants able I make to this. money think with to everybody

growth we be grow going to everybody those year. those they're going be that's amount grow I to to So to be significant feel the give that every sample each revenues of us grow month. have, don't and just able will each together revenue every half are, and will the as for each enough we'll right to to installations demonstrate we for accumulated And are have half and We increased to put significant of initial or have every The continue what once show the the enough looking enough revenues that and numbers showing a from which significant we continue think have second understand. now installations we're you volumes that and volumes we're for year, But month, revenue second going significant. the these which that's and month.

Operator

with next [ from comes Partners. Capital ] Cameron question Our Arslan ROTH

Unknown Analyst

My Arslan, Partners. I'm questions. Jason of for Capital on couple ROTH name a had from I Wittes is

can you get the quarter. average capacity? My on And how space? long well some congrats be up as color is last questions full quickly any capacity? with in the to there FDA FDA are reach larger versus to what And that, running? sites out competitors the are, provide customers to competitors Before go how do And my as dropped the these any able is new full are you new for likely Have expected what centers, and emerging to more question on purchase? anticipate

Joseph Sardano

Michael?

Michael Sardano

sure. Yes,

as So in was again, question I cutting out. it as your and apologize, far first

Unknown Analyst

Sure. Are competitors any the new dropping there out? into space, emerging any competitors

Michael Sardano

Got it.

competitors Again, the cancer surgery. other the with around. a That's to X is always States, all the And been no, mole larger really combined, United cancers than has enough unfortunately, X the skin main in which So the cancers competitor same have in alternative. times year million dermatology always been go market really that there's in. new it's

SRT to about very it's competitors, and talk stay. treatment, a is you when dermatology of way in very, unique here So and it's

So competitive either, dropped question. on I much groups. And have Agreement know touched large Deal out your that's not if nature Fair there's then you competitors there.

geography to what under And cash and the in is, way. is is. their that's these goal private saying, It them. been goal roll-ups practices. geared that more have, allows Agreement large buying That's really get is more we've the this private entire equity-backed groups, utilize the equity program the their I what expand roll-ups we think their Deal practices that Fair backed to that roll-up -- like for

that. from want it this groups. Joe, We're of always in discussions and really So with targets them, add? types XXXX in getting to interest -- about those anything excited more we're do you

Joseph Sardano

the interest maximize to installations, the each would they because where put in center, their Regarding group as revenues placements they is these want each well. again, evaluating

the the that for and already able on of that based of place where sites, for we've have So to analytics each some they provide themselves one analytics with to to based best we're along that these we're them start, sites process begun is the installing in able their calculate and on those analytics.

think to So for second are I the that of to themselves, going again, revenue I significant volumes it's going think half take year. and our the care provide again of

Unknown Analyst

do Just follow-up. largest purchase customer? to your would at it anticipate continuing of them a sales came What in similar be you a percent from And pace? XXXX? And

Joseph Sardano

just had They units continue delivered. came to quick. XX Let from largest me customer. We real buy. answer XX our

We buy expect throughout continue to to them the year.

we And forward so another look year. to, successful again,

Operator

comes Markets. Our Capital Lake Haynor Ben with question Street next from

Benjamin Haynor

large of for you've was clinics of might I that on interest these -- Can pencil gotten? might to how on seen color the private have a some bit you kind groups me, these little in discussions for or of help on investors more gauge be how advanced future? the from off customers. First equity level wondering kind Anything many that provide

Michael Sardano

to it? or Joe, want Sure. take one that you me want

Joseph Sardano

Yes.

private keep roll-ups there. dermatology. equity-backed an you currently that on are and about in overview, out to XX day. of X,XXX for that XX give clinics Let major That's me and on and between thanks the overall up the thanks question. call, clinics for represent those every about being day. the growing XX% belong and or every They clinics, There's There's new opened clinics Ben, being closing

clinics. looking XX% you're X,XXX of that's And so if that, at

looked over of exist the out being And X to is there. years, to next of so XX% -- growing number X and that clinics the overall at progression the

can is large, you see the vast. market long. So it's It's that

so product the their best And feel And that to accelerate XXXX. going suits it's needs. that course we the we that think have of we during

Fair now Deal that of have customers Agreement. the are these We several considering

gaining process. hopefully, of groups some access private SRT so the patients is those the focusing be installations see we end, here most be and a how to gaining that and as are most we'll talk money for important patients in year within of sides, to thing they most progress, We the access number that many Michael on And previously the as to continues that start we'll the that's equity-backed by because to the lot going those what able on progress able about mentioned, to to to want customers, being can to have. But important. be and what's try produces focus both treated and that's we'll

Michael Sardano

Ben, the that just Yes. And to around is add absolutely right. edges to answer, Joe

you If already we announced signed that group. we November, in remember large a

a out I few that have in out. to happily there. signed. And plans a So that's products the large that tell started roll -- do sites we group can you they've already rolling We're of some

of exciting us. all for that's So

In boards CEOs medical advisory roll-up given to addition, private equity-backed groups. of major or dermatology presentations X other we've and large X very

that's as far as So at progression. where we're

largest our capital our it be from shows a X sales. and fact standpoint, in QX, typically approach be the we that to with really could like in sales history with see X that out dermatology think happened I is really, of slingshot a our

sales, I think to FDA on convincing I I'm the and the process it's private easier and has sign -- when so looking been to an Deal Fair groups equity-backed run it, Agreement. physicians sales at

Benjamin Haynor

in future, metric. giving looking That's sort agreements right on, the anything and plan for you metric exactly the the of is what mentioned I patients-treated number of very like signed not helpful. Okay. a you Do or And was that?

Joseph Sardano

very be significant able Once very, numbers it, to to show I think important. that's think I do. that's progress what we the want we have to of

I think we'll get there.

Benjamin Haynor

waiting kind around and to have of [indiscernible] x for out And ready Do of ramp? Or SRT that and the patients. like then of? ramped x how volume, already where continue patients if But volumes there a let's they there, or yet do you -- does a these is month do out at? have I have you sense month the the over to of do number gotten that level treat month. that they over kind those how you patients high mentioned, imagine how folks ones they of And do is then are another see of in that solution believe kind would

Joseph Sardano

They that a it's think I works. know proven it technology.

think factor keep analysis to mistakes. And organizations. make the and any in takes biggest it want work big the I to organizations. mind, together don't time these the with They they're is

and well So the effective as They're things they especially the well-managed us right mistake, the kick the as good very, very off analytics the make off profitable valuation and target right really of what a allows wants bat. to They're for them. centers cost do. is so very everything at productive data Nobody organizations. to to that

very they've appreciative the we're that so And process implemented. of

as about rather it we never is fast. want at installed think it as that anything. it's we fast as to going. yesterday. the We beginning the replacing we're No, installed way But so things have right go? I'd to I want Now think don't have the units that's And

going for sites that a going we're they're real receptivity think to into. the I good have

bat. have good we're to right the So success going real off

Michael Sardano

remind I And things if everyone add, to just want X Yes. inventory. I about Joe. to our may,

visions, XX over just paid far well to including as for go as We visions. units have ready

ready up trained those from to another X regulatory. doing XX they it's a up about training standpoint, XX% leg go. we're as the site to of sites, from all patient get side remind it in the gives us that from process, the the of from then installed this immediately time unit to same and far receiving that just setting And the to there. standpoint. that, things, units Deal right, capital from sign is state a the to revenues an and We to And treatment of is The now It Agreement insurance the in up we've years. from as addition can Fair to weeks to XX XX days out takes that everyone money. the process equipment collect time takes So everyone been first then

it's collection, to day And industry XX seeing in So going from days. go treating the to insurance patient that's the that's expectations, where start the first to set you're live standpoint. an I revenues. of XX want the -- to on From very normal that's

Benjamin Haynor

the it's once to months X door. the dollars in signed, effectively in build So see

Michael Sardano

Exactly.

in revenues. And the of delay the so that's seeing some

Benjamin Haynor

fees perfect. Or That's much G&A step-up leave in of out you onetime-ish kind of this. professional how lastly higher I level of new for rate? can't kind compensation And and more me, run then the a was in Javier this nature? impacting quantify Okay. Can is

Javier Rampolla

No.

fees, professional a QX. onetime, the that the during doing it's we were different projects On

in compensation, adjustment. XXXX, And bit but G&A the a onetime expect we much a saw also to as was On in I as not QX. it little increase

Operator

to concludes this like question-and-answer session. the turn Sardano questions, for further I closing conference back would Joe No over remarks. to our any

Joseph Sardano

We Alliance you to coming on our updating by our progress hesitate headed Relations don't out great. Well, entire the quarters. performance of you Partners. the And questions, to XXXX. year Tirth any if reach at in have additional the us proud for we've Listen, for for you, that the quarter had very joining today. look to thank we're forward Again, everyone, last up Investor and team

today thank for so joining Sensus continued of us again support Operator? Healthcare. And you for and

Operator

presentation. you. Thank for now today's conference concluded. attending Thank has you The

disconnect. may now You

Sensus Healthcare (SRTS) 5 Feb 252024 Q4 Earnings call transcript